BioMarin Roctavian label ‘looks clean,’ says Truist

After BioMarin announced Roctavian was approved by the FDA for severe hemophilia A, Truist analyst Robyn Karnauskas said the label “looks clean” and noted there is no black box or REMS and three-year data is in the label. The firm, which remains Buy rated with a $140 price target on the shares, models peak sales of $830M in U.S. and $740M in EU with a wholesale acquisition cost price of about $2.5M in U.S. and says it awaits color on pricing.